Back to top
more

QuidelOrtho (QDEL)

(Real Time Quote from BATS)

$25.27 USD

25.27
790,316

+1.59 (6.72%)

Updated Aug 6, 2025 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.

Zacks Equity Research

QuidelOrtho (QDEL) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 28.57% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Zacks Equity Research

QuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.

Zacks Equity Research

QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.

Zacks Equity Research

QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

Zacks Equity Research

QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada

by Zacks Equity Research

QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.

Zacks Equity Research

QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China

by Zacks Equity Research

QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.

Zacks Equity Research

Are Investors Undervaluing PetIQ (PETQ) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks.com featured highlights Boyd Gaming, Expeditors International of Washington, QuidelOrtho, LPL Financial and Cboe Global Markets

by Zacks Equity Research

Boyd Gaming, Expeditors International of Washington, QuidelOrtho, LPL Financial and Cboe Global Markets have been highlighted in this Screen of The Week article.

Swayta Shah headshot

5 Stocks With Solid Sales Growth to Fight Economic Slowdown

by Swayta Shah

Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Boyd Gaming (BYD), Expeditors International (EXPD), QuidelOrtho (QDEL), LPL Financial (LPLA) and Cboe Global (CBOE), which are recording top-line growth.

Zacks Equity Research

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

QuidelOrtho (QDEL) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

Zacks.com featured highlights include Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors

by Zacks Equity Research

Crocs, Unum Group, QuidelOrtho, LPL Financial Holdings and Clean Harbors are part of the Zacks Screen of the Week article.

Swayta Shah headshot

5 Stocks With Solid Sales Growth to Navigate Volatile Markets

by Swayta Shah

Sales growth is vital for the survival of a business, even during an economic slowdown. Let's check Crocs (CROX), Unum (UNM), QuidelOrtho (QDEL), LPL Financial (LPLA) and Clean Harbors (CLH), which are witnessing top-line growth.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges (Revised)

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

Zacks Equity Research

Is QuidelOrtho (QDEL) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics

by Zacks Equity Research

QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.